Clinical Testing News and Research

RSS

Amped up antibiotic to fight resistant bacteria finally a reality

Resistant bacteria have been a menace killing thousands worldwide. Bacteria causing pneumonia, tuberculosis, wound and skin infections, gonorrhea have notably undergone major changes to evade the current armament of antibiotics that physicians have to fight them with.

30 May 2017

FDA approves new AML drug after clinical testing at Dana-Farber

A targeted drug whose clinical testing was led by Richard Stone, MD, of Dana-Farber Cancer Institute, has become the first new treatment for newly diagnosed acute myeloid leukemia (AML) in more than 25 years.

5 May 2017

UAB spinoff develops drug-resistant immunotherapy to combat solid tumors

The University of Alabama at Birmingham and two partner institutions have received a European patent for their novel approach to fighting cancer, an approach that is led by the UAB spinoff biopharmaceutical company Incysus Ltd.

5 May 2017

New poster presented at ASCB shows power of Phasefocus’ Livecyte label-free cell analysis system

Phasefocus provides a range of products and services based on its proprietary Ptychographic Quantitative Phase Imaging technology to provide a wide range of analytical applications including label-free cell imaging and quantitative electron phase microscopy.

From Phase Focus Limited 4 May 2017

Invivoscribe receives FDA approval for the LeukoStrat CDx FLT3 mutation assay companion diagnostic test for the selection of patients for Rydapt

Invivoscribe® Technologies Inc., a global company with more than 20 years of experience providing clonality and biomarker test solutions for the fields of oncology, personalized molecular diagnostics® and personalized molecular medicine®, today announces the premarket approval of LeukoStrat® CDx FLT3 Mutation Assay.

3 May 2017

Early blood test can predict vaccine immunogenicity

Within seven days of vaccination, a blood test early after vaccination can predict whether vaccines based on living, modified viruses have had the desired effect.

26 Apr 2017

UTSW researchers develop new nanoparticle vaccine immunotherapy that targets multiple tumor types

Researchers from UT Southwestern Medical Center have developed a first-of-its-kind nanoparticle vaccine immunotherapy that targets several different cancer types.

24 Apr 2017

Drug shows early promise in treating patients with small-cell lung cancer

An early round of clinical testing shows that users of Opdivo, a drug sanctioned for treatment of small-cell lung cancer, more than tripled their five-year survival rate beyond the statistical average.

20 Apr 2017

Researchers use stem cells to model different genetic scenarios that underlie neurologic disease

Researchers at Case Western Reserve University School of Medicine have successfully grown stem cells from children with a devastating neurological disease to help explain how different genetic backgrounds can cause common symptoms.

30 Mar 2017

First-of-its-kind mouse model could help study post-malaria epilepsy in children

A first-of-its-kind mouse model could lead to an understanding of how cerebral malaria infection leads to the development of epilepsy in children, and to the prevention of seizures.

23 Mar 2017

NeoGenomics, Definiens expand alliance to develop novel biomarker assays for clinical trials and testing

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, and Definiens, the leader in Tissue Phenomics solutions from biomarker discovery to meaningful diagnostics, today announced that they have expanded their alliance to develop and automate the analysis of new biomarker assays for clinical trials and routine clinical testing.

20 Mar 2017

Exact replication studies may accelerate development of better cancer treatments

In response to rising concern that many published scientific results may be false, the Reproducibility Project: Cancer Biology set out to replicate findings from the 50 most cited cancer studies from 2010-2012.

15 Mar 2017

Study finds new drug treatment to be safe and well-tolerated in pediatric patients with anxiety

A pilot study of guanfacine, a controlled-release alpha2-agonist, in children and adolescents with general, separation-related, and social anxiety disorder showed the drug to be safe and well-tolerated and provided preliminary evidence of its potential effectiveness.

1 Mar 2017

NR could potentially prevent chemotherapy-induced peripheral neuropathy in cancer patients

A new study in rats suggests that nicotinamide riboside (NR), a form of vitamin B3, may be useful for treating or preventing nerve pain (neuropathy) caused by chemotherapy drugs.

24 Feb 2017

Compound from snail's venom may offer alternative to opioids for pain relief

A tiny snail may offer an alternative to opioids for pain relief. Scientists at the University of Utah have found a compound that blocks pain by targeting a pathway not associated with opioids.

21 Feb 2017

Researcher finds new ways to adapt corn protein-based drug delivery method to pediatric medications

Developing medications for children can be challenging—taste and texture are important, but safety is also a major concern, according to pharmaceutical sciences professor Om Perumal at South Dakota State University.

13 Feb 2017

Researchers develop microfluidic device to study interactions between drugs and cells in kidneys

Instead of running tests on live kidneys, researchers at Binghamton, University State University of New York have developed a model kidney for working out the kinks in medicines and treatments.

9 Feb 2017

Cancer drug could promote regeneration of damaged heart muscle, research shows

An anticancer agent in development promotes regeneration of damaged heart muscle 0- an unexpected research finding that may help prevent congestive heart failure in the future.

3 Feb 2017

Cellectricon, Censo Biotechnologies launch joint technology access program to accelerate CNS and pain research

Cellectricon AB and Censo Biotechnologies Ltdare announcing the introduction of a joint technology access program for a fully humanized phenotypic screening platform targeting preclinical neuroscience and chronic pain research.

28 Jan 2017

TSRI scientists receive $1.8 million grant to develop drug candidates for multiple diseases

Scientists from the Florida campus of The Scripps Research Institute have been awarded approximately $1.8 million from the National Institute of General Medical Sciences of the National Institutes of Health to develop a series of drug candidates for a number of diseases, including heart disease, rheumatoid arthritis and several neurodegenerative disorders.

24 Jan 2017